FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892079741> ?p ?o ?g. }

• W2892079741 abstract "Abstract Background Docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy can have severe adverse events, including neutropenia and febrile neutropenia. Feasibility of DCF is a concern especially for elderly patients, patients with moderate organ disorder, and those with dysphagia or insufficient oral intake causing malnutrition. We introduced biweekly DCF therapy (bDCF) for the purpose of reducing severe adverse events for these fragile patients. This study investigated the feasibility and efficacy of bDCF therapy for patients with advanced esophageal squamous cell carcinoma who underwent radical esophagectomy after chemotherapy. Methods The parent DCF regimen consisted of 60–70 mg/m2 of docetaxel on day 1, administered intravenously for 2 h; 80 mg/m2 of cisplatin on day 1, administered intravenously for 2 h; and 5-fluorouracil administered by continuous infusion at a dose of 800 mg/m2 on days 1–5. The DCF regimen was repeated every 3–4 weeks. The bDCF regimen consisted of docetaxel (30 mg/m2) on days 1 and 15 in combination with cisplatin (80 mg/m2 on day 1) and 5-fluorouracil (800 mg/m2 on days 1–5), repeated every 4 weeks. Results Thirty-seven patients were treated with the DCF regimen (DCF group) and 22 patients were treated with the bDCF regimen (bDCF group). The age of patients was significantly higher in the bDCF group than in the DCF group. The bDCF group had more patients with heart and pulmonary comorbidities. Biweekly DCF group was significantly higher in the clinical response rate (DCF group 62.2% vs. bDCF group 86.4%, P = 0.0472). Grade 3 or 4 neutropenia was less frequent in the bDCF group (40.9%) than in the pDCF group (81.1%) (P = 0.0016). Among non-hematologic toxicities, anorexia was less frequent in the bDCF group (0%) than in the pDCF group (18.9%) (P = 0.0298). There were no significant differences between the groups in postoperative morbidity rate (bDCF group 45.5% vs. pDCF group 32.4%). Conclusion Preoperative bDCF therapy was feasible and safety without reduction of the efficacy of DCF therapy for fragile patients such as elderly patients, patients with moderate functional disorder, and that with malnutrition caused by dysphagia or insufficient oral intake. Disclosure All authors have declared no conflicts of interest." @default.
• W2892079741 created "2018-09-27" @default.
• W2892079741 creator A5011517986 @default.
• W2892079741 creator A5015429847 @default.
• W2892079741 creator A5022604285 @default.
• W2892079741 creator A5024937729 @default.
• W2892079741 creator A5031837496 @default.
• W2892079741 creator A5042824097 @default.
• W2892079741 creator A5065680139 @default.
• W2892079741 creator A5069688918 @default.
• W2892079741 creator A5069823683 @default.
• W2892079741 creator A5073818598 @default.
• W2892079741 creator A5078927270 @default.
• W2892079741 creator A5082526715 @default.
• W2892079741 creator A5084820122 @default.
• W2892079741 creator A5090408259 @default.
• W2892079741 creator A5091180256 @default.
• W2892079741 date "2018-09-01" @default.
• W2892079741 modified "2023-09-27" @default.
• W2892079741 title "PS02.122: PREOPERATIVE CHEMOTHERAPY WITH BIWEEKLY DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL FOR ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA" @default.
• W2892079741 doi "https://doi.org/10.1093/dote/doy089.ps02.122" @default.
• W2892079741 hasPublicationYear "2018" @default.
• W2892079741 type Work @default.
• W2892079741 sameAs 2892079741 @default.
• W2892079741 citedByCount "0" @default.
• W2892079741 crossrefType "journal-article" @default.
• W2892079741 hasAuthorship W2892079741A5011517986 @default.
• W2892079741 hasAuthorship W2892079741A5015429847 @default.
• W2892079741 hasAuthorship W2892079741A5022604285 @default.
• W2892079741 hasAuthorship W2892079741A5024937729 @default.
• W2892079741 hasAuthorship W2892079741A5031837496 @default.
• W2892079741 hasAuthorship W2892079741A5042824097 @default.
• W2892079741 hasAuthorship W2892079741A5065680139 @default.
• W2892079741 hasAuthorship W2892079741A5069688918 @default.
• W2892079741 hasAuthorship W2892079741A5069823683 @default.
• W2892079741 hasAuthorship W2892079741A5073818598 @default.
• W2892079741 hasAuthorship W2892079741A5078927270 @default.
• W2892079741 hasAuthorship W2892079741A5082526715 @default.
• W2892079741 hasAuthorship W2892079741A5084820122 @default.
• W2892079741 hasAuthorship W2892079741A5090408259 @default.
• W2892079741 hasAuthorship W2892079741A5091180256 @default.
• W2892079741 hasConcept C126322002 @default.
• W2892079741 hasConcept C141071460 @default.
• W2892079741 hasConcept C197934379 @default.
• W2892079741 hasConcept C2776694085 @default.
• W2892079741 hasConcept C2777063308 @default.
• W2892079741 hasConcept C2778850193 @default.
• W2892079741 hasConcept C2780456651 @default.
• W2892079741 hasConcept C2781190966 @default.
• W2892079741 hasConcept C2781413609 @default.
• W2892079741 hasConcept C71924100 @default.
• W2892079741 hasConcept C90924648 @default.
• W2892079741 hasConceptScore W2892079741C126322002 @default.
• W2892079741 hasConceptScore W2892079741C141071460 @default.
• W2892079741 hasConceptScore W2892079741C197934379 @default.
• W2892079741 hasConceptScore W2892079741C2776694085 @default.
• W2892079741 hasConceptScore W2892079741C2777063308 @default.
• W2892079741 hasConceptScore W2892079741C2778850193 @default.
• W2892079741 hasConceptScore W2892079741C2780456651 @default.
• W2892079741 hasConceptScore W2892079741C2781190966 @default.
• W2892079741 hasConceptScore W2892079741C2781413609 @default.
• W2892079741 hasConceptScore W2892079741C71924100 @default.
• W2892079741 hasConceptScore W2892079741C90924648 @default.
• W2892079741 hasLocation W28920797411 @default.
• W2892079741 hasOpenAccess W2892079741 @default.
• W2892079741 hasPrimaryLocation W28920797411 @default.
• W2892079741 hasRelatedWork W1990897966 @default.
• W2892079741 hasRelatedWork W1999001699 @default.
• W2892079741 hasRelatedWork W2469261890 @default.
• W2892079741 hasRelatedWork W2735933086 @default.
• W2892079741 hasRelatedWork W2891587599 @default.
• W2892079741 hasRelatedWork W2993396470 @default.
• W2892079741 hasRelatedWork W3036680471 @default.
• W2892079741 hasRelatedWork W3111826816 @default.
• W2892079741 hasRelatedWork W3214939470 @default.
• W2892079741 hasRelatedWork W4237179769 @default.
• W2892079741 isParatext "false" @default.
• W2892079741 isRetracted "false" @default.
• W2892079741 magId "2892079741" @default.
• W2892079741 workType "article" @default.